Details for Patent: RE43580
Summary for Patent: RE43580
| Title: | Nasal calcitonin formulations |
| Abstract: | A liquid pharmaceutical composition is disclosed comprising calcitonin or an acid addition salt thereof and citric acid or salt thereof in a concentration from about to about 50 mM, said composition being in a form table for nasal administration.A liquid pharmaceutical composition is provided for nasal administration of calcitonin or an acid addition salt thereof. The nasal pharmaceutical formulations contain a component selected from the group consisting of citric acid, citric acid salt and a combination thereof. |
| Inventor(s): | William Stern |
| Assignee: | Enteris Biopharma Inc |
| Application Number: | US12/459,385 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Delivery; |
| Patent landscape, scope, and claims: |
More… ↓ |
Drugs Protected by US Patent RE43580
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent RE43580
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 3660401 | ⤷ Start Trial | |||
| Australia | 783952 | ⤷ Start Trial | |||
| Canada | 2399505 | ⤷ Start Trial | |||
| China | 1183965 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
